



Mirati Therapeutics
Investor Relations Department
9393 Towne Centre Drive
Suite 200 Tel.: 858.332.3410
San Diego, CA 92121
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: MRTX

Last Trade:	5.35
Trade Time:	3:24 PM ET Aug 21, 2017
Change:	-0.25 ↓ (-4.464%)
Day Range	5.30 - 5.65
52-Week Range	2.70 - 7.22
Volume	62,510


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Mirati Therapeutics is a targeted oncology company developing therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths. Mirati is currently advancing three drug candidates through clinical development for multiple oncology indications. Mirati trades on the NASDAQ under the ticker symbol "MRTX."

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- [Aug 3, 2017
Mirati Therapeutics Reports Second Quarter 2017 Financial Results](#)
- [Jul 5, 2017
Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York](#)
- [Jun 27, 2017
Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors](#)
- [May 31, 2017
Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference](#)
- [May 4, 2017
Mirati Therapeutics Reports First Quarter 2017 Financial Results](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- [Mar 9, 2017
Annual Report \(10-K\)](#)
- [Apr 20, 2017
Proxy Statement \(DEF 14A\)](#)
- [Aug 3, 2017
Quarterly Report \(10-Q\)](#)
- [May 4, 2017
Quarterly Report \(10-Q\)](#)
- [Nov 3, 2016
Quarterly Report \(10-Q\)](#)